Pharming Group NV Cash Flow Conversion Efficiency
Pharming Group NV cash flow conversion efficiency. Based on the latest financial reports, Pharming Group NV (PHARM) has a cash flow conversion efficiency ratio of 0.121x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€32.03 Million ≈ $37.44 Million USD) by net assets (€264.64 Million ≈ $309.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pharming Group NV (2005–2024)
Cash flow conversion efficiency of Pharming Group NV from 2005 to 2024. This chart illustrates how Pharming Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pharming Group NV (PHARM) stock price for real-time trading data and today's change.
Pharming Group NV Cash Flow Conversion Ratio Explained
Pharming Group NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pharming Group NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharming Group NV ranked by their cash flow conversion efficiency. Also see market cap of Pharming Group NV for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ASGN Inc
NYSE:ASGN
|
0.047x |
|
FAWER Automotive Parts Ltd Co
SHE:000030
|
0.028x |
|
Equital
TA:EQTL
|
0.020x |
|
Jiangsu Wuyang Parking Industry Group Co Ltd
SHE:300420
|
0.010x |
|
Genomma Lab Internacional S.A.B. de C.V
MX:LABB
|
-0.020x |
|
BlackRock Credit Allocation Income Trust
NYSE:BTZ
|
0.029x |
|
Orient International Enterprise Ltd
SHG:600278
|
0.007x |
|
Baota Industry Co Ltd
SHE:000595
|
0.327x |
Annual Cash Flow Conversion Efficiency for Pharming Group NV (2005–2024)
The table below shows the annual cash flow conversion efficiency of Pharming Group NV from 2005 to 2024. Review Pharming Group NV free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €214.16 Million ≈ $250.38 Million |
€-1.79 Million ≈ $-2.10 Million |
-0.008x | +91.51% |
| 2023-12-31 | €198.05 Million ≈ $231.55 Million |
€-19.55 Million ≈ $-22.85 Million |
-0.099x | -188.20% |
| 2022-12-31 | €204.64 Million ≈ $239.24 Million |
€22.90 Million ≈ $26.77 Million |
0.112x | -40.31% |
| 2021-12-31 | €192.72 Million ≈ $225.31 Million |
€36.13 Million ≈ $42.23 Million |
0.187x | -62.14% |
| 2020-12-31 | €183.73 Million ≈ $214.80 Million |
€90.98 Million ≈ $106.36 Million |
0.495x | -22.12% |
| 2019-12-31 | €117.26 Million ≈ $137.09 Million |
€74.56 Million ≈ $87.16 Million |
0.636x | -2.76% |
| 2018-12-31 | €70.64 Million ≈ $82.58 Million |
€46.19 Million ≈ $54.00 Million |
0.654x | -67.83% |
| 2017-12-31 | €22.56 Million ≈ $26.37 Million |
€45.84 Million ≈ $53.60 Million |
2.032x | +658.01% |
| 2016-12-31 | €28.89 Million ≈ $33.77 Million |
€-10.52 Million ≈ $-12.30 Million |
-0.364x | +47.13% |
| 2015-12-31 | €26.06 Million ≈ $30.47 Million |
€-17.95 Million ≈ $-20.99 Million |
-0.689x | -289.43% |
| 2014-12-31 | €36.29 Million ≈ $42.43 Million |
€-6.42 Million ≈ $-7.50 Million |
-0.177x | +89.31% |
| 2013-12-31 | €6.92 Million ≈ $8.09 Million |
€-11.45 Million ≈ $-13.39 Million |
-1.655x | -223.33% |
| 2012-12-31 | €-10.12 Million ≈ $-11.83 Million |
€-13.58 Million ≈ $-15.88 Million |
1.342x | -89.84% |
| 2011-12-31 | €-1.54 Million ≈ $-1.80 Million |
€-20.34 Million ≈ $-23.78 Million |
13.210x | +2676.91% |
| 2010-12-31 | €13.43 Million ≈ $15.70 Million |
€-6.89 Million ≈ $-8.05 Million |
-0.513x | +64.11% |
| 2009-12-31 | €19.07 Million ≈ $22.30 Million |
€-27.24 Million ≈ $-31.85 Million |
-1.428x | -75.31% |
| 2008-12-31 | €17.45 Million ≈ $20.40 Million |
€-14.21 Million ≈ $-16.62 Million |
-0.815x | -30.04% |
| 2007-12-31 | €50.58 Million ≈ $59.13 Million |
€-31.69 Million ≈ $-37.05 Million |
-0.626x | -59.15% |
| 2006-12-31 | €65.78 Million ≈ $76.91 Million |
€-25.89 Million ≈ $-30.27 Million |
-0.394x | +12.20% |
| 2005-12-31 | €34.04 Million ≈ $39.79 Million |
€-15.26 Million ≈ $-17.84 Million |
-0.448x | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more